Afayro 20mg Tablet

Afayro 20mg tablet is used in the treatment of non-small cell lung cancer (NSCLC) whose tumor show particular mutations in Epidermal growth factor (EGFR), the medication directly targeting this mutation caused enzyme and preventing them from multiplying, slowing tumor growth and helping to control the progression of the disease. The medication active ingredient is Afatinib and belongs to the class of anti-cancer medication known as tyrosine kinase inhibitor. Doctor prescribed this medication as a part of a targeted therapy plan to inhibit cancer cell growth in patients with EGFR mutated NSCLC.

Non small cell lung cancer

Like every other medication Afayro 20mg tablet also show various side effects, also not everyone experience them but consult the doctor if any of these are persist:
● Interstitial lung disease (ILD)
● Severe diarrhea or dehydration
● Liver problems
● Eye problems, such as corneal erosion or ulceration
● Hemorrhage or bleeding problems
● Kidney problems
● Cardiac problems
● Diarrhea
● Mouth sores
● Acne or skin rash
● Nausea and vomiting
● Fatigue

Afayro 20mg tablet is an oral medication designed to take it on an empty stomach at the same time everyday to enhance the effectiveness of the treatment. Do not miss a dose but if you do then skip the missed dose and continue with the regular schedule. Doctor will guide you better about the dose and duration based on the patient's medical history. It is important to follow all the medical instructions carefully and repost any unusual side effects the healthcare provider.

EGFR is an enzyme in the human body which is responsible for the growth of cancer cells. Afayro 20mg tablet is an anticancer drug that specifically targets the EGFR mutated gene and binding that. Hence, it stops the production of tumor cells, thereby slowing or stopping the production of cancer cells and preventing the body from further growing cancer in the body.

• WAEC, N., & a Doctor, C. Cytogard 20mg Tablet 10? S.
• Park, K., Tan, E. H., O'Byrne, K., Zhang, L., Boyer, M., Mok, T., ... & Paz-Ares, L. (2016). Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. The Lancet Oncology, 17(5), 577-589.
• Solca, F., Dahl, G., Zoephel, A., Bader, G., Sanderson, M., Klein, C., ... & Adolf, G. R. (2012). Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. The Journal of pharmacology and experimental therapeutics, 343(2), 342-350.
• Harvey, R. D., Adams, V. R., Beardslee, T., & Medina, P. (2020). Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings. Journal of Oncology Pharmacy Practice, 26(6), 1461-1474.
• Schuler, M., Yang, J. H., Park, K., Kim, J. H., Bennouna, J., Chen, Y. M., ... & Popovych, O. (2016). Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Annals of Oncology, 27(3), 417-423.